Literature DB >> 32527092

NIAID's Comprehensive Support Mechanisms for Antibiotic Development.

Erin M Zeituni1, Erica L Raterman1.   

Abstract

The National Institute of Allergy and Infectious Diseases (NIAID) recognizes the continuing threat of antimicrobial resistance and the need to develop new therapeutics and strategies to combat multidrug resistant organisms. NIAID leverages multiple mechanisms to help support antibiotic developers struggling in the "valley of death" of preclinical antibiotic development. The Division of Microbiology and Infectious Diseases' (DMID) preclinical services are a comprehensive set of services to facilitate efforts to develop vaccines, diagnostics, and therapeutics for a broad array of bacterial, viral, fungal, and parasitic pathogens. These services are available to investigators worldwide at no charge.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32527092     DOI: 10.1021/acsinfecdis.0c00099

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  1 in total

1.  There is no market for new antibiotics: this allows an open approach to research and development.

Authors:  Dana M Klug; Fahima I M Idiris; Mark A T Blaskovich; Frank von Delft; Christopher G Dowson; Claas Kirchhelle; Adam P Roberts; Andrew C Singer; Matthew H Todd
Journal:  Wellcome Open Res       Date:  2021-06-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.